References
1. Craig, W.A., Pharmacokinetic/Pharmacodynamic Parameters:
Rationale for Antibacterial Dosing of Mice and Men. Clinical Infectious
Diseases, 1998. 26 (1): p. 1-12.
2. Blot, S.I., F. Pea, and J. Lipman, The effect of
pathophysiology on pharmacokinetics in the critically ill patient —
Concepts appraised by the example of antimicrobial agents. Advanced
Drug Delivery Reviews, 2014. 77 : p. 3-11.
3. Briscoe, S.E., et al., A method for determining the free
(unbound) concentration of ten beta-lactam antibiotics in human plasma
using high performance liquid chromatography with ultraviolet
detection. Journal of Chromatography B, 2012. 907 : p. 178-184.
4. Colman, S., et al., Measuring Unbound Versus Total Piperacillin
Concentrations in Plasma of Critically Ill Patients: Methodological
Issues and Relevance. Ther Drug Monit, 2019. 41 (3): p.
325-330.
5. Wong, G., et al., Protein Binding of B-Lactam Antibiotics in
Critically Ill Patients: Can We Successfully Predict Unbound
Concentrations? 2013. 57 (12): p. 6165-6170.
6. Al-Shaer, M.H., et al., Meropenem, Cefepime, and Piperacillin
Protein Binding in Patient Samples. Ther Drug Monit, 2020.42 (1): p. 129-132.
7. Roberts, D.M., et al., A multicenter study on the effect of
continuous hemodiafiltration intensity on antibiotic pharmacokinetics.Critical Care, 2015. 19 (1): p. 84.
8. Ulldemolins, M., et al., Piperacillin population
pharmacokinetics in critically ill patients with multiple organ
dysfunction syndrome receiving continuous venovenous haemodiafiltration:
effect of type of dialysis membrane on dosing requirements. J
Antimicrob Chemother, 2016. 71 (6): p. 1651-9.
9. Hayashi, Y., et al., Pharmacokinetic evaluation of
piperacillin-tazobactam. Expert Opinion on Drug Metabolism &
Toxicology, 2010. 6 (8): p. 1017-1031.
10. El-Haffaf, I., et al., Using a Validated Population
Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion
Piperacillin for Critically Ill Adult Patients. Clinical
Pharmacokinetics, 2022.
11. Klastrup, V., et al., Population Pharmacokinetics of
Piperacillin following Continuous Infusion in Critically Ill Patients
and Impact of Renal Function on Target Attainment. Antimicrob Agents
Chemother, 2020. 64 (7).
12. Roberts, J.A., F. Pea, and J. Lipman, The clinical relevance
of plasma protein binding changes. Clin Pharmacokinet, 2013.52 (1): p. 1-8.
13. Al-Shaer, M.H., et al., Meropenem, Cefepime, and Piperacillin
Protein Binding in Patient Samples. 2020. 42 (1): p. 129-132.
14. Colman, S., et al., Measuring Unbound Versus Total
Piperacillin Concentrations in Plasma of Critically Ill Patients:
Methodological Issues and Relevance. 2019. 41 (3): p. 325-330.
15. Klastrup, V., et al., Population Pharmacokinetics of
Piperacillin following Continuous Infusion in Critically Ill Patients
and Impact of Renal Function on Target Attainment. Antimicrobial Agents
and Chemotherapy, 2020. 64 (7): p. e02556-19.
16. Guang, W., M. Baraldo, and M. Furlanut, Calculating percentage
prediction error: A user’s note. Pharmacological Research, 1995.32 (4): p. 241-248.
17. Varvel, J.R., D.L. Donoho, and S.L. Shafer, Measuring the
predictive performance of computer-controlled infusion pumps. Journal
of Pharmacokinetics and Biopharmaceutics, 1992. 20 (1): p.
63-94.
18. Ulldemolins, M., et al., The effects of hypoalbuminaemia on
optimizing antibacterial dosing in critically ill patients. Clin
Pharmacokinet, 2011. 50 (2): p. 99-110.
19. Chen, I.H. and D.P. Nicolau, Augmented Renal Clearance and How
to Augment Antibiotic Dosing. Antibiotics (Basel, Switzerland), 2020.9 (7): p. 393.
20. El-Haffaf, I., J.-A. Caissy, and A. Marsot,Piperacillin-Tazobactam in Intensive Care Units: A Review of
Population Pharmacokinetic Analyses. Clinical Pharmacokinetics, 2021.60 (7): p. 855-875.
21. Felton, T.W., et al., Impact of Bolus dosing versus continuous
infusion of Piperacillin and Tazobactam on the development of
antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents
Chemother, 2013. 57 (12): p. 5811-9.
22. Sumi, C.D., et al., What Antibiotic Exposures Are Required to
Suppress the Emergence of Resistance for Gram-Negative Bacteria? A
Systematic Review. Clin Pharmacokinet, 2019. 58 (11): p.
1407-1443.
23. Asín-Prieto, E., et al., Population pharmacokinetics of
piperacillin and tazobactam in critically ill patients undergoing
continuous renal replacement therapy: application to
pharmacokinetic/pharmacodynamic analysis. Journal of Antimicrobial
Chemotherapy, 2013. 69 (1): p. 180-189.